Menu
Your Cart

HER2 ELISA Kit

HER2 ELISA Kit
HER2 ELISA Kit
  • Stock: In Stock
$690.00

Available Options

Description

HER2 ELISA Kit 

Catalog Number: HER2-01-1154

Size: 1 plate (96 wells)

HER2 ELISA Kit is a sandwich enzyme-linked immunoassay for the quantitative determination of HER2 with high sensitivity and specificity in serum or plasma.

   

Kit Performance

  • Sensitivity: 10 pg/mL
  • Assay Range: 10 – 1000 pg/mL
  • Cross-reactivity: There is no cross reaction with native immunoglobulins
  • Recovery rate: 80 – 120% with normal human serum or plasma samples with known concentrations.
  • Precision

(CV (%) = SD/mean X 100)

  • Intra-Assay: CV < 20%
  • Inter-Assay: CV < 20%

Materials Supplied

List of component

Components

  Quantity

High binding Plate

  1 plate

HER2

  1 µg

10x Capture

  700 µL

10x Detection

  700 µL

1x Streptavidin (HRP) (Avoid light)

  12 mL

1x Plate Coating Buffer

  15 mL

1x Blocking Buffer

  15 mL

2x Assay Diluent

  30 mL

1x TMB Substrate (Avoid light)

  12 mL

1x Stop Solution

  12 mL

 

Storage Instruction

The components arrive with ice pack, and must immediately be stored at 2-8°C. The kit components are stable at the date specified in CoA.

 

Supplementary information

HER2 (Human Epidermal Growth Factor Receptor 2), also known as ERBB2, is a receptor tyrosine kinase located on the cell membrane. Unlike most receptor tyrosine kinases, HER2 does not have a known ligand and is naturally in a conformation that readily forms dimers with other ERBB receptors.

When HER2 forms homodimers or heterodimers—especially with HER3—it activates several downstream signaling pathways that control cell proliferation and survival. The most important pathways include the PI3K–AKT pathway, which promotes cell survival and resistance to apoptosis, and the MAPK/ERK pathway, which stimulates cell proliferation.

In cancer, the ERBB2 gene becomes amplified, leading to overexpression of HER2 protein on the cell surface. HER2 amplification occurs in approximately 15–20% of breast cancers and in a subset of gastric and esophageal cancers. Tumors with HER2 overexpression often show more aggressive biological behavior but are also highly responsive to targeted therapies.